HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Inclusion Criteria: * HIV-1 infected * Viral load of 500 copies/mL or more * Prior HAART for more than 7 days, but less than 40 weeks during at least one previous pregnancy for prevention of MTCT of HIV * Clinical or laboratory indication to start HAART, in the opinion of the participant's physician * Certain laboratory values * Willingness to use acceptable forms of contraception * Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: * Taking any antiretroviral medication within 24 weeks prior to study entry * Evidence of certain HIV-1 RT mutations within 90 days prior to study entry (version 1.0) * Evidence of certain HIV-1 RT mutations identified by standard bulk viral population genotypic resistance tests at any time prior to study entry, if available (version 2.0, 09/03/2009) * Treatment at any time, for any reason with nevirapine as a single agent OR addition of any part of the study regimen as a single agent to a failing regimen * Use of certain antihistamines, certain anti-infectives, cisapride, St John's wort, midazolam, triazolam, dihydroergotamine, ergonovine, ergotamine, or methylergonovine within 14 days prior to study entry * Use of HIV vaccine, chronic systemic corticosteroids, interleukins, interferons, other cytokines, or investigational therapy within 30 days prior to study entry * Acute or chronic therapy for certain serious medical illnesses within 14 days of study entry. Participants who have completed 7 days of therapy and are judged clinically stable are not excluded. * Cancer requiring systemic chemotherapy * Known allergy/sensitivity to the study drugs or their formulations * Current drug or alcohol use that, in the opinion of the investigator, would interfere with the study * Two consecutive HIV viral loads of more than 5,000 copies/mL 8 weeks or more following initiation of HAART during pregnancy and while still receiving HAART * Two consecutive viral loads of more than 400 copies/mL 24 weeks or more following initiation of HAART during pregnancy while still receiving HAART * Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness * Pregnancy or breastfeeding